Oncternal Therapeutics Inc. buy Brookline Capital Management
Start price
04.12.23
/
50%
€0.31
Target price
04.12.24
€1.85
Performance (%)
3.23%
End price
05.12.24
-
Summary
This prediction is currently being closed. The BUY prediction by Brookline_Capital_Ma shows slight gains of 3.23%. Brookline_Capital_Ma has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Oncternal Therapeutics Inc. | - | - | - |
| iShares Core DAX® | 0.751% | -8.496% | 2.575% |
| iShares Nasdaq 100 | -1.405% | -2.771% | 15.682% |
| iShares Nikkei 225® | 0.417% | -9.291% | 29.655% |
| iShares S&P 500 | -0.590% | -2.868% | 9.963% |
Comments by Brookline_Capital_Ma for this prediction
In the thread Oncternal Therapeutics Inc. diskutieren
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock.
Ratings data for ONCT provided by MarketBeat
In the thread Trading Oncternal Therapeutics Inc.
Die von Brookline_Capital_Ma gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Brookline_Capital_Ma for Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.70
11.03.23
11.03.23
-
11.03.24
11.03.24
-62.03%
12.03.24
12.03.24
